Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Spooner

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Cell Biophysics|January 1, 1993
A universal antibody-derived targeting agentR A Spooner, M P Deonarain, P Savage, et al.
Cell Biophysics|January 1, 1994
Deoxyribonuclease I (DNAse I). A novel approach for targeted cancer therapyH Linardou, M P Deonarain, R A Spooner, et al.
Molecular Immunology|February 1, 1994
Expression of immunoglobulin heavy chain-ricin A chain fusions in mammalian cellsR A Spooner, D J Allen, A A Epenetos, et al.
Cancer Gene Therapy|November 4, 2000
In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrugR A Spooner, J Martin, F Friedlos, et al.
Cancer Research|October 15, 1996
Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combinationR Marais, R A Spooner, Y Light, et al.
Nature Biotechnology|January 7, 1998
A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapyR Marais, R A Spooner, S M Stribbling, et al.
International Journal of Cancer|June 8, 2001
Appropriate subcellular localisation of prodrug-activating enzymes has important consequences for suicide gene therapyR A Spooner, K A Maycroft, H Paterson, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 1, 1996
A single-chain Fv reactive with the Goodpasture antigenC N Ross, N Turner, P Savage, et al.
Human Pathology|June 1, 1994
Genetically engineered antibodies for diagnostic pathologyR A Spooner, S Murray, G Rowlinson-Busza, et al.
Human Gene Therapy|February 19, 2000
Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effectS M Stribbling, F Friedlos, J Martin, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Cell Biophysics|January 1, 1993
A universal antibody-derived targeting agentR A Spooner, M P Deonarain, P Savage, et al.
Cell Biophysics|January 1, 1994
Deoxyribonuclease I (DNAse I). A novel approach for targeted cancer therapyH Linardou, M P Deonarain, R A Spooner, et al.
Molecular Immunology|February 1, 1994
Expression of immunoglobulin heavy chain-ricin A chain fusions in mammalian cellsR A Spooner, D J Allen, A A Epenetos, et al.
Cancer Gene Therapy|November 4, 2000
In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrugR A Spooner, J Martin, F Friedlos, et al.
Cancer Research|October 15, 1996
Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combinationR Marais, R A Spooner, Y Light, et al.
Nature Biotechnology|January 7, 1998
A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapyR Marais, R A Spooner, S M Stribbling, et al.
International Journal of Cancer|June 8, 2001
Appropriate subcellular localisation of prodrug-activating enzymes has important consequences for suicide gene therapyR A Spooner, K A Maycroft, H Paterson, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 1, 1996
A single-chain Fv reactive with the Goodpasture antigenC N Ross, N Turner, P Savage, et al.
Human Pathology|June 1, 1994
Genetically engineered antibodies for diagnostic pathologyR A Spooner, S Murray, G Rowlinson-Busza, et al.
Human Gene Therapy|February 19, 2000
Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effectS M Stribbling, F Friedlos, J Martin, et al.
Pageof 3